-
公开(公告)号:US20060030588A1
公开(公告)日:2006-02-09
申请号:US11210291
申请日:2005-08-24
申请人: Andrew Stamford , Youhao Dong , Stuart McCombie , Yusheng Wu
发明人: Andrew Stamford , Youhao Dong , Stuart McCombie , Yusheng Wu
IPC分类号: A61K31/4545 , C07D41/14
CPC分类号: C07D401/12 , C07D213/75 , C07D401/14 , C07D403/12 , C07D409/12 , C07D409/14 , C07D417/04 , C07D417/12 , C07D417/14
摘要: The present invention relates to compounds represented by the structural Formula I: or a pharmaceutically acceptable salt thereof, which are useful for the treatment of metabolic and eating disorders such as obesity and hyperphagia, and for the treatment of diabetes and associated disorders.
-
公开(公告)号:US07807672B2
公开(公告)日:2010-10-05
申请号:US11705709
申请日:2007-02-13
申请人: Yongqi Deng , Gerald W. Shipps, Jr. , Alan Cooper , Yang Nan , Tong Wang , M. Arshad Siddiqui , Hugh Zhu , Robert Sun , Joseph M. Kelly , Ronald Doll , Jagdish Desai , James J-S Wang , Youhao Dong , Vincent Madison , Li Xiao , Alan Hruza , Neng-Yang Shih
发明人: Yongqi Deng , Gerald W. Shipps, Jr. , Alan Cooper , Yang Nan , Tong Wang , M. Arshad Siddiqui , Hugh Zhu , Robert Sun , Joseph M. Kelly , Ronald Doll , Jagdish Desai , James J-S Wang , Youhao Dong , Vincent Madison , Li Xiao , Alan Hruza , Neng-Yang Shih
IPC分类号: A61K31/506 , A61K31/5377 , A61K31/4025 , A61K31/496 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D413/12 , C07D417/06 , C07D417/12
CPC分类号: C07D207/16 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D487/08
摘要: Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substituents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
摘要翻译: 公开了式1.0的ERK抑制剂及其药学上可接受的盐和溶剂化物。 Q是可以具有桥或稠合环的哌啶或哌嗪环。 哌啶环可以在环中具有双键。 所有其它取代基如本文所定义。 还公开了使用式1.0化合物治疗癌症的方法。
-
公开(公告)号:US20090118284A1
公开(公告)日:2009-05-07
申请号:US11810282
申请日:2007-06-05
申请人: Alan B. Cooper , Yongqi Deng , Gerald W. Shipps, JR. , Neng-Yang Shih , Hugh Y. Zhu , Robert Sun , Joseph M. Kelly , Ronald J. Doll , Yang Nan , Tong Wang , Jagdish A. Desai , James J-S Wang , Youhao Dong , Vincent S. Madison , Li Xiao , Alan W. Hruza , M. Arshad Siddiqui , Ahmed A. Samatar , Sunil Paliwal , Hon-Chung Tsui , Azim Alan Celebi , Yiji Wu , Sobhana Babu Boga , Abdul-Basit Alhassan , Xiaolei Gao , Liang Zhu , Mehul Patel
发明人: Alan B. Cooper , Yongqi Deng , Gerald W. Shipps, JR. , Neng-Yang Shih , Hugh Y. Zhu , Robert Sun , Joseph M. Kelly , Ronald J. Doll , Yang Nan , Tong Wang , Jagdish A. Desai , James J-S Wang , Youhao Dong , Vincent S. Madison , Li Xiao , Alan W. Hruza , M. Arshad Siddiqui , Ahmed A. Samatar , Sunil Paliwal , Hon-Chung Tsui , Azim Alan Celebi , Yiji Wu , Sobhana Babu Boga , Abdul-Basit Alhassan , Xiaolei Gao , Liang Zhu , Mehul Patel
IPC分类号: A61K31/496 , C07D403/14 , C07D413/14 , A61K31/506 , A61P35/00 , A61P35/02 , A61K31/4439 , A61K31/5377 , C07D401/14
CPC分类号: C07D231/56 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/14
摘要: Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
摘要翻译: 公开了式1.0的ERK抑制剂及其药学上可接受的盐,酯和溶剂化物。 Q是可以具有桥或稠合环的哌啶或哌嗪环。 哌啶环可以在环中具有双键。 所有其他取代基如本文所定义。 还公开了使用式1.0化合物治疗癌症的方法。
-
公开(公告)号:US07705153B2
公开(公告)日:2010-04-27
申请号:US11049460
申请日:2005-02-02
申请人: Pauline C. Ting , Jianhua Cao , Youhao Dong , Eric J. Gilbert , Ying Huang , Joseph M. Kelly , Stuart McCombie , Neng-Yang Shih
发明人: Pauline C. Ting , Jianhua Cao , Youhao Dong , Eric J. Gilbert , Ying Huang , Joseph M. Kelly , Stuart McCombie , Neng-Yang Shih
IPC分类号: A61K31/4709 , A61K31/4725 , C07D215/14
CPC分类号: C07D401/14 , C07D211/18 , C07D211/58 , C07D401/04 , C07D471/04
摘要: The use of CCR3 antagonists of the formula I or a pharmaceutically acceptable salt thereof for the treatment of asthma is disclosed, as well as novel compounds of the formula II, pharmaceutical compositions comprising them, and their use in the treatment of asthma, wherein R, Ra, X, Xa, R1, R2, R2a, R14, R14a, R16 and n are as defined in the specification.
摘要翻译: 公开了使用式I的CCR3拮抗剂或其药学上可接受的盐治疗哮喘,以及式II的新型化合物,包含它们的药物组合物及其在治疗哮喘中的用途,其中R, Ra,X,Xa,R1,R2,R2a,R14,R14a,R16和n如说明书中所定义。
-
公开(公告)号:US07309704B2
公开(公告)日:2007-12-18
申请号:US11210291
申请日:2005-08-24
申请人: Andrew Stamford , Youhao Dong , Stuart W. McCombie , Yusheng Wu
发明人: Andrew Stamford , Youhao Dong , Stuart W. McCombie , Yusheng Wu
IPC分类号: C07D239/24 , C07D403/04 , C07D403/12 , C07D403/14 , A61K31/506 , A61P3/04
CPC分类号: C07D401/12 , C07D213/75 , C07D401/14 , C07D403/12 , C07D409/12 , C07D409/14 , C07D417/04 , C07D417/12 , C07D417/14
摘要: The present invention relates to compounds represented by the structural Formula I: or a pharmaceutically acceptable salt thereof, which are useful for the treatment of metabolic and eating disorders such as obesity and hyperphagia, and for the treatment of diabetes and associated disorders.
摘要翻译: 本发明涉及由结构式I表示的化合物或其药学上可接受的盐,其可用于治疗代谢和进食障碍如肥胖症和食欲过盛,以及用于治疗糖尿病和相关疾病。
-
公开(公告)号:US08546404B2
公开(公告)日:2013-10-01
申请号:US11810282
申请日:2007-06-05
申请人: Alan B. Cooper , Yongqi Deng , Gerald W. Shipps, Jr. , Neng-Yang Shih , Hugh Y. Zhu , Robert Sun , Joseph M. Kelly , Ronald J. Doll , Yang Nan , Tong Wang , Jagdish A. Desai , James J-S Wang , Youhao Dong , Vincent S. Madison , Li Xiao , Alan W. Hruza , M. Arshad Siddiqui , Ahmed A. Samatar , Sunil Paliwal , Hon-Chung Tsui , Azim Alan Celebi , Yiji Wu , Sobhana Babu Boga , Abdul-Basit Alhassan , Xiaolei Gao , Liang Zhu , Mehul Patel
发明人: Alan B. Cooper , Yongqi Deng , Gerald W. Shipps, Jr. , Neng-Yang Shih , Hugh Y. Zhu , Robert Sun , Joseph M. Kelly , Ronald J. Doll , Yang Nan , Tong Wang , Jagdish A. Desai , James J-S Wang , Youhao Dong , Vincent S. Madison , Li Xiao , Alan W. Hruza , M. Arshad Siddiqui , Ahmed A. Samatar , Sunil Paliwal , Hon-Chung Tsui , Azim Alan Celebi , Yiji Wu , Sobhana Babu Boga , Abdul-Basit Alhassan , Xiaolei Gao , Liang Zhu , Mehul Patel
IPC分类号: A01N43/54 , C07D239/42 , C07D401/04
CPC分类号: C07D231/56 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/14
摘要: Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
摘要翻译: 公开了式1.0的ERK抑制剂及其药学上可接受的盐,酯和溶剂化物。 Q是可以具有桥或稠合环的哌啶或哌嗪环。 哌啶环可以在环中具有双键。 所有其他取代基如本文所定义。 还公开了使用式1.0化合物治疗癌症的方法。
-
公开(公告)号:US20070232610A1
公开(公告)日:2007-10-04
申请号:US11705709
申请日:2007-02-13
申请人: Yongqi Deng , Gerald Shipps , Alan Cooper , Yang Nan , Tong Wang , M. Siddiqui , Hugh Zhu , Robert Sun , Joseph Kelly , Ronald Doll , Jagdish Desai , James Wang , Youhao Dong , Vincent Madison , Li Xiao , Alan Hruza , Neng-Yang Shih
发明人: Yongqi Deng , Gerald Shipps , Alan Cooper , Yang Nan , Tong Wang , M. Siddiqui , Hugh Zhu , Robert Sun , Joseph Kelly , Ronald Doll , Jagdish Desai , James Wang , Youhao Dong , Vincent Madison , Li Xiao , Alan Hruza , Neng-Yang Shih
IPC分类号: A61K31/53 , A61K31/506 , A61K31/502 , A61K31/497 , A61K31/4439 , A61K31/407 , A61K31/401 , C07D403/02
CPC分类号: C07D207/16 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D487/08
摘要: Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
-
公开(公告)号:US20070191604A1
公开(公告)日:2007-08-16
申请号:US11636954
申请日:2006-12-11
申请人: Alan Cooper , Yongqi Deng , Gerald Shipps , Neng-Yang Shih , Hugh Zhu , Robert Sun , Joseph Kelly , Ronald Doll , Yang Nan , Tong Wang , Jagdish Desai , James Wang , Youhao Dong , Vincent Madison , Li Xiao , Alan Hruza , M. Siddiqui , Ahmed Samatar , Sunil Paliwal , Hon-Chung Tsui , Azim Celebi , Yiji Wu , Sobhana Boga
发明人: Alan Cooper , Yongqi Deng , Gerald Shipps , Neng-Yang Shih , Hugh Zhu , Robert Sun , Joseph Kelly , Ronald Doll , Yang Nan , Tong Wang , Jagdish Desai , James Wang , Youhao Dong , Vincent Madison , Li Xiao , Alan Hruza , M. Siddiqui , Ahmed Samatar , Sunil Paliwal , Hon-Chung Tsui , Azim Celebi , Yiji Wu , Sobhana Boga
IPC分类号: C07D417/14 , C07D413/14 , C07D403/14
CPC分类号: C07D405/14 , C07D231/56 , C07D401/14 , C07D403/12 , C07D403/14 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/14
摘要: Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.
摘要翻译: 公开了式1.0的ERK抑制剂及其药学上可接受的盐和溶剂化物。 Q是可以具有桥或稠合环的哌啶或哌嗪环。 哌啶环可以在环中具有双键。 所有其他取代基如本文所定义。 还公开了使用式1.0化合物治疗癌症的方法。
-
公开(公告)号:US06982267B2
公开(公告)日:2006-01-03
申请号:US10026651
申请日:2001-12-18
申请人: Andrew Stamford , Youhao Dong , Stuart W. McCombie , Yusheng Wu
发明人: Andrew Stamford , Youhao Dong , Stuart W. McCombie , Yusheng Wu
IPC分类号: C07D241/26 , C07D409/04 , A61K31/4965 , A61K31/497 , A61K3/04
CPC分类号: C07D401/12 , A61K31/4523 , A61K31/4535 , A61K31/4545 , A61K31/497 , A61K31/501 , A61K31/506 , A61K45/06 , C07D401/14 , C07D403/12 , C07D409/12 , C07D409/14 , C07D417/12 , C07D417/14 , A61K2300/00
摘要: The present invention relates to compounds represented by the structural Formula I: or a pharmaceutically acceptable salt thereof, which are useful for the treatment of metabolic and eating disorders such as obesity and hyperphagia, and for the treatment of diabetes and associated disorders.
-
公开(公告)号:US06946476B2
公开(公告)日:2005-09-20
申请号:US10177345
申请日:2002-06-20
申请人: Andrew Stamford , Youhao Dong , Stuart W. McCombie , Yusheng Wu
发明人: Andrew Stamford , Youhao Dong , Stuart W. McCombie , Yusheng Wu
IPC分类号: A61K31/4523 , A61K31/4535 , A61K31/4545 , A61K31/497 , A61K31/501 , A61K31/506 , A61K45/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D409/12 , C07D409/14 , C07D417/12 , C07D417/14 , C07D213/02 , A61K31/4418 , A61K31/4436 , A61P3/04 , C07D409/04
CPC分类号: C07D401/12 , C07D213/75 , C07D401/14 , C07D403/12 , C07D409/12 , C07D409/14 , C07D417/04 , C07D417/12 , C07D417/14
摘要: The present invention relates to compounds represented by the structural Formula I: or a pharmaceutically acceptable salt thereof, which are useful for the treatment of metabolic and eating disorders such as obesity and hyperphagia, and for the treatment of diabetes and associated disorders.
摘要翻译: 本发明涉及由结构式I表示的化合物或其药学上可接受的盐,其可用于治疗代谢和进食障碍如肥胖症和食欲过盛,以及用于治疗糖尿病和相关疾病。
-
-
-
-
-
-
-
-
-